Fosamax and Osteonecrosis of the Jaw: Understanding the Biological Plausibility and Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Communication to Targeted Risk Awareness

The legacy of general health and science communication has long emphasized the importance of informed decision-making and risk awareness across diverse populations. Within this tradition, public health messaging has consistently aimed to translate complex biomedical concepts into accessible guidance, fostering a baseline understanding of how various exposures may influence health outcomes. This foundational approach has proven valuable in contexts ranging from dietary recommendations to pharmaceutical safety, where the goal is to empower individuals with knowledge that supports prudent choices. As this heritage demonstrates, the transition from broad health education to more specialized risk considerations often requires a careful reframing of familiar principles. In the present context, this involves shifting focus from general health maintenance to a more targeted examination of how specific exposures—such as those encountered in occupational settings—may carry distinct implications. The same logic that underpins general health literacy now directs attention toward understanding the potential consequences of sustained contact with certain agents in the workplace. This pivot does not abandon the legacy of accessible science communication; rather, it applies its core tenets to a narrower domain, where the need for clarity and caution is equally pressing. By building on established practices of risk communication, the transition to occupational exposure concern becomes a natural extension of prior efforts to promote health awareness.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on this foundation of risk communication, we now turn to a specific pharmaceutical exposure: Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibition of bone resorption by osteoclasts, which reduces bone turnover. While this effect is beneficial for increasing bone mass and reducing fracture risk, it has been associated with a rare but serious adverse event: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves pain, swelling, infection, and exposed bone that fails to heal after dental procedures. Diagnosis is based on clinical examination and imaging, with a focus on ruling out metastatic disease or other causes of jaw lesions.

Biological Plausibility: Mechanistic Pathways

The biological plausibility linking Fosamax to ONJ is supported by several mechanistic pathways. Bisphosphonates, including Fosamax, accumulate in bone tissue, particularly in areas of high bone turnover such as the jaw. The jawbone undergoes constant remodeling due to mechanical stress from chewing and the presence of teeth. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Research using estrogen-deficient rat models has examined the effects of bisphosphonate (alendronate) treatment on jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These studies suggest that bisphosphonate therapy alters the mechanical and structural properties of jawbone, potentially predisposing it to necrosis. The primary mechanistic pathway involves suppression of osteoclast activity. By inhibiting osteoclast-mediated bone resorption, Fosamax reduces the ability of the jawbone to remodel and repair microdamage. This is particularly problematic in the jaw, where dental procedures, infections, or trauma can create a need for bone healing. The reduced turnover impairs the removal of necrotic bone and the formation of new bone, leading to non-healing lesions. Additionally, bisphosphonates have anti-angiogenic properties, which may compromise blood supply to the jawbone, further contributing to tissue death.

Risk Factors and Clinical Evidence

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw. It states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of bisphosphonate use for ONJ risk reduction, only stating that the optimal duration of use for osteoporosis treatment has not been determined and that for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations for Affected Patients

Causation considerations for affected patients involve several factors. The timeline between exposure and documented harm can vary widely. The time to onset of symptoms after starting Fosamax has been reported to range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ typically develops after longer-term use, often years of exposure. Most patients have relief of symptoms after stopping the drug, but a subset may experience recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event that may not be captured in typical clinical trial populations. For patients who develop ONJ, establishing causation requires careful assessment of exposure history, including duration of Fosamax use, presence of other risk factors (e.g., dental procedures, cancer, corticosteroid use), and exclusion of other causes. The biological plausibility is supported by the known effects of bisphosphonates on bone turnover and jawbone-specific responses. However, the rarity of ONJ and the presence of multiple risk factors complicate individual causation determinations. Patients should be informed of the potential risk, especially if they require invasive dental procedures, and healthcare providers should consider dental evaluation before initiating bisphosphonate therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the biological plausibility linking Fosamax to osteonecrosis of the jaw?

The biological plausibility is supported by several mechanistic pathways. Bisphosphonates like Fosamax accumulate in bone tissue, particularly in areas of high bone turnover such as the jaw. They suppress osteoclast activity, reducing the jawbone's ability to remodel and repair microdamage, which is critical after dental procedures or trauma. Additionally, bisphosphonates have anti-angiogenic properties that may compromise blood supply, contributing to tissue death. Research using estrogen-deficient rat models has shown that alendronate treatment alters jawbone mechanical and structural properties, potentially predisposing it to necrosis (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the known risk factors for developing osteonecrosis of the jaw while taking Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate exposure.

How is causation established for Fosamax-related osteonecrosis of the jaw?

Causation requires careful assessment of exposure history, including duration of Fosamax use, presence of other risk factors (e.g., dental procedures, cancer, corticosteroid use), and exclusion of other causes. The timeline from exposure to symptom onset can vary widely, from days to months, but ONJ typically develops after years of use. Most patients improve after stopping the drug, but recurrence may occur upon rechallenge. The rarity of ONJ and multiple risk factors complicate individual causation determinations.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.